Format

Send to

Choose Destination
Eur J Cancer. 2006 Dec;42(18):3127-39. Epub 2006 Nov 13.

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

Author information

1
Erasmus University Medical Center, Department of Medical Oncology PO Box 2040, 3000 CA Rotterdam, Netherlands. f.eskens@erasmusmc.nl

Abstract

Clinical experience with vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors is rapidly increasing, and some compounds have already been approved for regular anticancer treatment. Apart from their activity, much attention has been focussed on the clinical toxicity profile of these compounds. This review describes the most frequently occurring side-effects of both antibodies and tyrosine kinase inhibitors and discusses some of the underlying mechanisms. Some practical guidelines for treatment of the side-effects are given.

PMID:
17098419
DOI:
10.1016/j.ejca.2006.09.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center